Hanger Reports Third Quarter 2020 Financial Results

Rhea-AI Summary

Hanger, Inc. (NYSE: HNGR) reported a net revenue decline of 8.2% to $256.6 million for Q3 2020, impacted by reduced patient volumes due to the COVID-19 pandemic. Net income rose to $6.8 million, with adjusted diluted EPS of $0.20, down from $0.25 in Q3 2019. The Patient Care segment's revenue fell 7.9%, while the Products & Services segment dropped 9.7%. Liquidity increased to $242.3 million. CEO Vinit Asar noted a recovery in patient volumes and effective cost containment measures. No guidance was provided due to ongoing pandemic uncertainties.

Positive

• Net income increased to $6.8 million, up from $5.7 million in Q3 2019.
• Adjusted diluted EPS was $0.20 compared to $0.15 in the prior year.
• Liquidity improved to $242.3 million, up $39.6 million since June 30, 2020.
• Patient volumes showed improvement with a lower average decline in appointments from 33% to 16%.

Negative

• Net revenue dropped by 8.2% compared to Q3 2019.
• Same clinic revenue on a day-adjusted basis declined by 10.3%.
• Patient Care net revenue decreased by 7.9%, primarily from lower prosthetics and orthotics sales.
• Adjusted EBITDA fell to $27.9 million from $32.6 million in Q3 2019.

AUSTIN, Texas--(BUSINESS WIRE)--Hanger, Inc. (NYSE: HNGR), a leading provider of orthotic and prosthetic (O&P) patient care services and solutions, today announced its financial results for the third quarter ended September 30, 2020.

Financial Highlights

• Net revenue was $256.6 million for the three months ended September 30, 2020, compared to $279.6 million for the same period in 2019, reflecting a decrease of 8.2 percent. Net same clinic revenue on a day-adjusted basis declined by 10.3 percent, due primarily to a decrease in patient volumes associated with the COVID-19 pandemic.

• Net income was $6.8 million for the three months ended September 30, 2020, compared to $5.7 million for the same period in 2019. Income from operations was $13.1 million for the quarter compared to $17.4 million for the same period in 2019.

• Adjusted EBITDA was $27.9 million in the third quarter of 2020, compared to $32.6 million for the same period in 2019, reflecting a decline of $4.8 million.

• GAAP diluted earnings per share was $0.18 for the third quarter of 2020, compared to $0.15 per diluted share for the same period in 2019. Adjusted diluted earnings per share was $0.20 for the three months ended September 30, 2020, compared to $0.25 per share for the same period in 2019.

• On September 30, 2020, the Company had $242.3 million in liquidity, reflecting an increase of $39.6 million as compared with June 30, 2020.

Vinit Asar, President and Chief Executive Officer of Hanger, Inc., stated, "Our patient volumes demonstrated continued recovery in the third quarter, and this, combined with the cost containment measures we took at the start of the pandemic, contributed to a favorable earnings and cash flow performance. Our employees have demonstrated strength and resilience in the face of these difficult times and their actions have positioned us well for 2021."

Complete reconciliations of GAAP to non-GAAP financial measures are provided in the tables located at the end of this press release.

Segment Results for Three Months Ended September 30, 2020

Patient Care Segment

For the three months ended September 30, 2020, Patient Care net revenue was $212.7 million, a decrease of $18.3 million, or 7.9 percent, compared to the same period in 2019. For the three month period, acquisitions of O&P clinics that were consummated in 2019 and 2020 contributed $4.4 million of revenue growth, net of consolidations.

Net same clinic revenue declined by 10.3 percent during the third quarter of 2020 compared to the same quarter in the prior year period. This reflected an improvement from the 18.7 percent decline reported during the second quarter of 2020. While patient care volumes remain lower than the prior year due to the impact of the COVID-19 pandemic, the Company experienced a gradual recovery in patient volumes during the quarter. Excluding acquisitions, net revenue from prosthetics declined 8.9 percent in the quarter and net revenue from orthotics declined 11.8 percent. While the percentage decline in prosthetics revenue as compared with the same periods in 2019 remained relatively consistent in the second and third quarters, revenue from orthotics services recovered significantly in the third quarter and was the primary contributing factor to the improvement in the Company's sequential quarterly revenue performance. Prosthetics comprised 55.5 percent of Patient Care segment net revenue during the third quarter of 2020 as compared to 54.8 percent during the same period in 2019.

During the months of July, August and September 2020, patient volumes decreased by approximately 18 percent, 17 percent and 13 percent, respectively, each as compared with their corresponding prior period in 2019. The average decline in patient appointments for the quarter was 16 percent, an improvement from 33 percent in the second quarter of 2020. As of September 30, 2020, the Company had temporarily closed 22 patient care clinics and another 84 clinics were open for reduced hours or by appointment only.

Income from operations in the Patient Care segment was $32.2 million during the third quarter of 2020, a decrease of $3.9 million compared to the $36.1 million reported in the prior year.

Adjusted EBITDA for the segment was $39.2 million, which reflected a $3.0 million or 7.0 percent decrease. Adjusted EBITDA margin in the segment totaled 18.4 percent compared to 18.3 percent during the third quarter of 2019.

Products & Services Segment

For the three months ended September 30, 2020, Products & Services net revenue totaled $44.0 million, a decline of 9.7 percent compared with the same period in 2019. Revenue from the distribution of O&P componentry declined by $3.9 million, or 10.8 percent, primarily from lower sales volumes due to the COVID-19 pandemic, and to a lesser extent, the Company's decision to exit the distribution of certain low margin off-the-shelf orthotics into third-party channels. Therapeutic solutions revenue declined $0.8 million, or 6.6 percent.

Income from operations for the Products & Services segment remained consistent with the third quarter of 2019 at $5.1 million. Adjusted EBITDA for the Products & Services segment totaled $8.2 million for the third quarter of 2020, a $0.1 million decrease compared with the same period of 2019. Adjusted EBITDA margin in the segment totaled 18.6 percent compared to 16.6 percent during the third quarter of 2019. Products & Services segment margins and earnings were positively affected by lower operating costs associated with temporary labor cost reductions.

Corporate & Other

Expenses associated with corporate and other activities increased by $0.4 million to $24.3 million for the quarter ended September 30, 2020 compared to the same period in 2019. Excluding the effect of depreciation and amortization, non-cash equity-based compensation expense and certain non-recurring expenses, the net cost of corporate and other activities increased by $1.9 million to $19.5 million in the third quarter of 2020.

Net Income; Interest Expense

Interest expense totaled $8.0 million for the three month period ended September 30, 2020, a decrease of $0.9 million from the prior year period.

For the three month period ended September 30, 2020, net income was $6.8 million compared with $5.7 million for the same period in 2019. GAAP diluted income per share was $0.18 compared to $0.15 per share in 2019. Adjusted diluted income per share was $0.20 for the three months ended September 30, 2020, compared to $0.25 per share for the same period in 2019.

Financial Highlights for the Nine Months Ended September 30, 2020

• Net revenue was $723.8 million for the nine months ended September 30, 2020, compared to $797.2 million for the same period of 2019, reflecting a net revenue decline of 9.2 percent. For the nine month period, acquisitions of O&P clinics that were consummated in 2019 and 2020 contributed $13.4 million of revenue growth, net of consolidations.

• Patient Care net revenue declined $54.0 million, or 8.3 percent, for the year-to-date period to $598.7 million, while same clinic day-adjusted net revenue per day declined 11.2 percent. Net revenue from prosthetics, excluding acquisitions, decreased 6.6 percent on a day-adjusted basis, while orthotics net revenue, excluding acquisitions, declined by 16.3 percent, also on a day-adjusted basis.

• Products & Services segment net revenue declined $19.4 million, or 13.4 percent, resulting from a decrease of $16.6 million, or 15.4 percent, in distribution services and a $2.8 million decrease, or 7.5 percent, in net revenue from therapeutic solutions.

• GAAP net income was $22.1 million for the nine months ended September 30, 2020, compared to $8.8 million for the same period in 2019. GAAP Patient Care segment results for the first nine months of 2020 included a benefit of $20.6 million to other operating costs related to the Company's receipt of CARES Act healthcare provider grants. These grants were received under the Public Health and Social Services Emergency fund, also referred to as The Provider Relief Fund, established by the CARES Act.

• Adjusted EBITDA of $69.7 million for the first nine months of 2020 was $12.2 million lower as compared to the $81.9 million reported in the prior year period. Adjusted EBITDA excludes the benefit of the CARES Act healthcare provider grants. The decline in Adjusted EBITDA is a result of lower patient volumes during March through September 2020 associated with the COVID-19 pandemic, partially offset by temporary cost reduction measures in personnel costs and other expense.

• For the nine months ended September 30, 2020, GAAP diluted earnings per share was $0.57 compared to $0.23 per share in 2019. Adjusted diluted earnings per share was $0.27 for the first nine months of 2020, compared to $0.45 per share for the same period in 2019.

Net Cash Provided by Operating Activities and Liquidity

Cash flows provided by operating activities for the three months ending September 30, 2020 were $45.2 million compared to $23.5 million for the same period in 2019. In addition to other factors, the Company benefited from improvements in cash collections during the third quarter of 2020 as its days sales outstanding decreased by four days to 43 days as of September 30, 2020 from 47 days on September 30, 2019.

On September 30, 2020, the Company had liquidity of $242.3 million, comprised of $147.5 million in cash and cash equivalents, and $94.8 million in available borrowing capacity under its revolving credit facility. This compares to total liquidity of $202.7 million on June 30, 2020.

Outlook Regarding the Effects of the COVID-19 Pandemic on Prospective Results

Beginning in April 2020, in response to the COVID-19 pandemic, the Company made certain changes to its operations, implemented a broad number of cost reduction measures, and temporarily delayed certain capital investment projects. Salaries for exempt employees were initially reduced by an average of 32 percent in April 2020. As volumes began to improve, one-third of this reduction was reinstated in June 2020, a further one-third was reinstated during July 2020, and the final outstanding 11 percent reduction in wages was reinstated at the end of the third quarter. The Company also commenced the gradual reduction of employee furloughs in June 2020 and completed the majority of these temporary furloughs at the end of the third quarter of 2020.

The restoration of these temporary salary reductions had the effect of increasing the Company's operating costs during the third quarter of 2020 as compared with the second quarter of 2020. The final one-third restoration will result in a further increase in personnel expenses for the fourth quarter of 2020 to levels that will approximate pre-pandemic amounts.

Management believes the remaining length and intensity of the pandemic is uncertain as is its future impact on patient volumes. Given the continuing uncertain and material effects the COVID-19 pandemic will likely have on prospective results, the Company is not providing guidance as to its anticipated financial results for the current year.

Conference and Webcast Details

The Company’s management team will host a conference call tomorrow, Thursday, November 5, at 8:30 a.m. Eastern time to discuss the Company’s third quarter 2020 financial results and business outlook.

To participate, dial 844-750-4896 or 412-317-5292 outside the U.S. and Canada, and ask to be joined into the Hanger, Inc. call. A live webcast, replay of the call and earnings release, will be available on the Company’s Investor Relations website: www.investor.hanger.com/financial-reporting.

Additional Notes

A reconciliation of GAAP and non-GAAP financial results is included in the tables provided at the back of this press release. The Company has provided certain supplemental key statistics relating to its results for certain prior periods. These key statistics are non-GAAP measures used by the Company’s management to analyze the Company’s business results that are being provided for informational and analytical context.

Accompanying supplemental information will be posted to the Investor Relations section of Hanger’s web site at www.hanger.com/investors.

About Hanger, Inc. - Hanger, Inc. (NYSE: HNGR) delivers orthotic and prosthetic (O&P) patient care, and distributes O&P products and rehabilitative solutions to the broader market. Hanger's Patient Care segment is the largest owner and operator of O&P patient care clinics with approximately 800 locations nationwide. Through its Products & Services segment, Hanger distributes branded and private label O&P devices, products and components, and provides rehabilitative solutions. With nearly 160 years of clinical excellence and innovation, Hanger's vision is to lead the orthotic and prosthetic markets by providing superior patient care, outcomes, services and value. For more information on Hanger, visit https://investor.hanger.com.

This earnings release contains statements that are forward-looking statements within the meaning of the federal securities laws. Forward-looking statements include information concerning our liquidity and our possible or assumed future results of operations, including descriptions of our business strategies. These statements often include words such as “believe,” “expect,” “project,” “potential,” “anticipate,” “intend,” “plan,” “estimate,” “seek,” “will,” “may,” “would,” “should,” “could,” “forecasts” or similar words. These statements are based on certain assumptions that we have made in light of our experience in the industry as well as our perceptions of historical trends, current conditions, expected future developments and other factors we believe are appropriate in these circumstances. We believe these assumptions are reasonable, but you should understand that these statements are not guarantees of performance or results, and our actual results could differ materially from those expressed in the forward-looking statements due to a variety of important factors, both positive and negative, that may be revised or supplemented in subsequent releases or reports. These statements involve risks, estimates, assumptions, and uncertainties that could cause actual results to differ materially from those expressed in these statements and elsewhere in this release. These uncertainties include, but are not limited to, the financial and business impacts of COVID-19 on our operations and the operations of our customers, suppliers, governmental and private payers and others in the healthcare industry and beyond; federal laws governing the health care industry; governmental policies affecting O&P operations, including with respect to reimbursement; failure to successfully implement a new enterprise resource planning system or other disruptions to information technology systems; the inability to successfully execute our acquisition strategy, including integration of recently acquired O&P clinics into our existing business; changes in the demand for our O&P products and services, including additional competition in the O&P services market; disruptions to our supply chain; our ability to enter into and derive benefits from managed-care contracts; our ability to successfully attract and retain qualified O&P clinicians; and other risks and uncertainties generally affecting the health care industry. For additional information and risk factors that could affect the Company, see its Form 10-K for the year ended December 31, 2019 and Quarterly Report on Form 10-Q for the three months ended September 30, 2020, each as filed with the Securities and Exchange Commission. The information contained in this press release is made only as of the date hereof, even if subsequently made available by the Company on its website or otherwise.

Table 1 Hanger, Inc. Condensed Consolidated Statements of Operations (Unaudited - in thousands, except share and per share amounts)
		For the Three Months Ended September 30,								For the Nine Months Ended September 30,
		2020				2019				2020				2019
Net revenues		$	256,637			$	279,638			$	723,810			$	797,155
Material costs		81,462				92,034				228,675				261,810
Personnel costs		89,727				94,594				252,734				272,795
Other operating costs (a)		29,935				32,771				74,098				100,067
General and administrative expenses		31,371				29,834				91,618				87,474
Professional accounting and legal fees		2,264				3,629				7,409				9,576
Depreciation and amortization		8,803				9,373				26,513				26,906
Income from operations		13,075				17,403				42,763				38,527
Interest expense, net		8,013				8,954				24,918				25,973
Non-service defined benefit plan expense		158				173				474				519
Income before income taxes		4,904				8,276				17,371				12,035
(Benefit) provision for income taxes		(1,911		)		2,585				(4,750		)		3,260
Net income		$	6,815			$	5,691			$	22,121			$	8,775
Basic and Diluted Per Common Share Data:
Basic earnings per share		$	0.18			$	0.15			$	0.58			$	0.24
Weighted average shares used to compute basic earnings per common share		38,133,598				37,349,144				37,878,753				37,218,234
Diluted earnings per share		$	0.18			$	0.15			$	0.57			$	0.23
Weighted average shares used to compute diluted earnings per common share		38,637,536				37,986,860				38,491,965				37,921,767

(a) For the nine months ended September 30, 2020, Hanger recognized approximately $20.6 million of income within other operating costs related to grant proceeds received under the CARES Act.

Table 2 Hanger, Inc. Condensed Consolidated Balance Sheets (Unaudited - in thousands)
		As of September 30,				As of December 31,
		2020				2019
ASSETS
Current assets:
Cash and cash equivalents		$	147,510			$	74,419
Accounts receivable, net		121,409				159,359
Inventories		74,108				68,204
Income taxes receivable		5,945				—
Other current assets		14,489				13,673
Total current assets		363,461				315,655
Non-current assets:
Property, plant, and equipment, net		86,637				84,057
Goodwill		271,701				232,244
Other intangible assets, net		19,106				17,952
Deferred income taxes		70,489				70,481
Operating lease right-of-use assets		125,577				110,559
Other assets		15,710				11,305
Total assets		$	952,681			$	842,253
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY
Current liabilities:
Current portion of long-term debt		$	27,791			$	8,752
Accounts payable		63,630				48,477
Accrued expenses and other current liabilities		72,434				55,825
Accrued compensation related costs		63,511				61,010
Current portion of operating lease liabilities		32,932				34,342
Total current liabilities		260,298				208,406
Long-term liabilities:
Long-term debt, less current portion		493,600				490,121
Operating lease liabilities		106,405				88,418
Other liabilities		60,077				45,804
Total liabilities		920,380				832,749
Shareholders’ equity:
Common stock		383				376
Additional paid-in capital		363,082				354,326
Accumulated other comprehensive loss		(20,400		)		(12,551		)
Accumulated deficit		(310,068		)		(331,951		)
Treasury stock, at cost		(696		)		(696		)
Total shareholders’ equity		32,301				9,504
Total liabilities and shareholders’ equity		$	952,681			$	842,253

Table 3 Hanger, Inc. Condensed Consolidated Statements of Cash Flows (Unaudited - in thousands)
		For the Nine Months Ended September 30,
		2020					2019
Cash flows provided by operating activities:
Net income		$	22,121				$	8,775
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization		26,513					26,906
Provision for doubtful accounts		629					284
Share-based compensation expense		15,565					10,089
Deferred income taxes		2,067					(723		)
Amortization of debt discounts and issuance costs		1,564					1,202
Gain on sale and disposal of fixed assets		(729		)			(1,200		)
Changes in operating assets and liabilities:
Accounts receivable, net		39,531					1,914
Inventories		(3,834		)			(6,310		)
Other current assets and other assets		(3,115		)			(1,769		)
Income taxes		(6,814		)			2,613
Accounts payable		12,912					(1,751		)
Accrued expenses and other current liabilities		6,914					(2,144		)
Accrued compensation related costs		2,339					(15,583		)
Other liabilities		8,016					(1,736		)
Operating lease liabilities, net of amortization of right-of-use assets		1,559					(622		)
Net cash provided by operating activities		125,238					19,945
Cash flows used in investing activities:
Acquisitions, net of cash acquired		(16,854		)			(31,585		)
Purchase of property, plant, and equipment		(19,352		)			(20,262		)
Purchase of therapeutic program equipment leased to third parties under operating leases		(3,194		)			(5,165		)
Proceeds from sale of property, plant, and equipment		1,578					2,181
Purchase of company-owned life insurance investment		(250		)			—
Net cash used in investing activities		(38,072		)			(54,831		)
Cash flows used in financing activities:
Borrowings under revolving credit agreement		79,000					—
Repayment of borrowings under revolving credit agreement		(79,000		)			—
Repayment of term loan		(3,788		)			(3,788		)
Payment of employee taxes on share-based compensation		(6,841		)			(3,710		)
Payment on seller notes		(2,200		)			(2,688		)
Payments of financing lease obligations		(521		)			(344		)
Payments under vendor financing arrangements		(550		)			—
Payment of debt issuance costs		(214		)			—
Proceeds from the exercise of options		39					249
Net cash used in financing activities		(14,075		)			(10,281		)
Increase (decrease) in cash and cash equivalents		73,091					(45,167		)
Cash and cash equivalents at beginning of period		74,419					95,114
Cash and cash equivalents at end of period		$	147,510				$	49,947

Table 4 Hanger, Inc. Segment Information: Revenue, EBITDA and Adjusted EBITDA (Unaudited - in thousands)

EBITDA is defined as operating income before depreciation and amortization. Adjusted EBITDA is defined as operating income before certain charges, third-party professional fees in excess of normal amounts incurred in connection with our financial statement remediation, expenses associated with equity-based compensation, severance expenses, certain expenses incurred in connection with our acquisitions, proceeds received from grants under the Coronavirus Aid, Relief and Economy Security Act ("CARES Act") and certain other charges.

We use EBITDA and Adjusted EBITDA as measures to assess the relative level of our indebtedness and our compliance with certain debt covenants which are based on these measures. Additionally, we utilize these measures to assess our operating and financial performance. We believe that these measures enhance a user’s understanding of normal operating income excluding certain charges, depreciation and amortization.

Neither EBITDA or Adjusted EBITDA are measures of financial performance computed in accordance with Generally Accepted Accounting Principles (“GAAP”) and should not be considered in isolation nor as a substitute for operating income, net income, cash flows from operations, or other statement of operations or cash flow data prepared in conformity with GAAP, or as a measure of profitability or liquidity. In addition, the calculation of EBITDA and Adjusted EBITDA is susceptible to varying interpretations and calculations, and the amounts presented may not be comparable to similarly titled measures of other companies. EBITDA and Adjusted EBITDA may not be indicative of historical operating results, and we do not intend these measures to be predictive of future results of operations.

		For the Three Months Ended September 30,										For the Nine Months Ended September 30,
		2020					2019					2020					2019
Net Revenue (a)
Patient Care		$	212,664				$	230,931				$	598,706				$	652,700
Products & Services		43,973					48,707					125,104					144,455
Net revenue		$	256,637				$	279,638				$	723,810				$	797,155
EBITDA (b)
Patient Care		$	37,024				$	41,073				$	116,483				$	107,658
Products & Services		7,754					7,834					20,842					21,995
Corporate & Other		(22,900		)			(22,131		)			(68,049		)			(64,220		)
EBITDA (Non-GAAP)		$	21,878				$	26,776				$	69,276				$	65,433
Adjusted EBITDA (b)
Patient Care		$	39,209				$	42,160				$	100,728				$	110,929
Products & Services		8,157					8,070					21,784					22,721
Corporate & Other		(19,505		)			(17,594		)			(52,860		)			(51,761		)
Adjusted EBITDA (Non-GAAP)		$	27,861				$	32,636				$	69,652				$	81,889
(a) Excludes intersegment revenue.
(b) EBITDA and Adjusted EBITDA are "Non-GAAP" measures. Please refer to both Table 6 and Table 7 for a reconciliation of these measures to GAAP net income.

Table 5 Hanger, Inc. Reconciliation of Net Income and Earnings Per Share to Adjusted Net Income and Adjusted Earnings Per Share (Unaudited - in thousands, except share and per share amounts)

Earnings Per Share (or “EPS”) is defined as net income divided by our basic or diluted common shares during the applicable period. Adjusted EPS is defined as EPS adjusted for certain equity-based compensation charges, third-party professional fees in excess of normal amounts incurred in connection with our financial statement remediation, severance expenses, certain expenses incurred in connection with our acquisitions, proceeds received from grants under the CARES Act, and certain other charges.

We utilize Adjusted EPS to assess our operating and financial performance. We believe that this measure enhances a user’s understanding of normal operating results excluding certain charges.

Adjusted EPS is not a measure of financial performance computed in accordance with GAAP and should not be considered in isolation nor as a substitute for operating income, net income, cash flows from operations, or other statement of operations or cash flow data prepared in conformity with GAAP, or as a measure of profitability or liquidity. In addition, the calculation of Adjusted EPS is susceptible to varying interpretations and calculations, and the amounts presented may not be comparable to similarly titled measures of other companies. Adjusted EPS may not be indicative of historical operating results, and we do not intend these measures to be predictive of future results of operations.

		For the Three Months Ended September 30,										For the Nine Months Ended September 30,
		2020					2019					2020					2019
Net income - as reported (GAAP)		$	6,815				$	5,691				$	22,121				$	8,775
Adjustments:
Modification of equity awards (a)		—					—					5,869					—
Amortization expense		1,797					1,561					5,071					3,917
Third-party professional fees		—					2,136					1,639					5,530
Acquisition-related expenses		33					350					405					848
Hanger supply chain implementation costs		376					—					806					—
Severance expenses		3,015					—					3,015					(11		)
Proceeds from grants under the CARES Act		(43		)			—					(20,576		)			—
Adjustments prior to tax effect		$	5,178				$	4,047				$	(3,771	)			$	10,284
Tax effect of specified adjustments (b)		(4,331		)			(373		)			(8,014		)			(2,097		)
Adjustments after taxes		847					3,674					(11,785		)			8,187
Adjusted net income (Non-GAAP)		$	7,662				$	9,365				$	10,336				$	16,962
Basic earnings per share - as reported (GAAP)		$	0.18				$	0.15				$	0.58				$	0.24
Effect of above listed specified adjustments		0.02					0.10					(0.31		)			0.22
Adjusted basic earnings per share - as reported (Non-GAAP)		$	0.20				$	0.25				$	0.27				$	0.46
Diluted earnings per share - as reported (GAAP)		$	0.18				$	0.15				$	0.57				$	0.23
Effect of above listed specified adjustments		0.02					0.10					(0.30		)			0.22
Adjusted diluted earnings per share - as reported (Non-GAAP)		$	0.20				$	0.25				$	0.27				$	0.45
Shares used to compute basic earnings per share		38,133,598					37,349,144					37,878,753					37,218,234
Shares used to compute diluted earnings per share		38,637,536					37,986,860					38,491,965					37,921,767

(a) Modification of equity awards reflect a non-recurring charge in the second quarter of 2020 for incremental equity-based compensation expense under ASC 718, Stock Compensation, related to the modification of certain equity awards granted in 2017.

(b) “Tax effect of specified adjustments” reflects the difference between the Company's effective provision for taxes and the application of a combined federal and state statutory tax rate of 24% for the 2020 and 2019 periods to the Company's earnings from operations before taxes, after the incorporation of the identified adjustments above.

Table 6 Hanger, Inc. Reconciliation of Net Income to EBITDA and Adjusted EBITDA (Unaudited - in thousands)

EBITDA is defined as operating income before depreciation and amortization. Adjusted EBITDA is defined as operating income before certain charges, third-party professional fees in excess of normal amounts incurred in connection with our financial statement remediation, expenses associated with equity-based compensation, severance expenses, certain expenses incurred in connection with our acquisitions, proceeds received from grants under the CARES Act and certain other charges.

We use EBITDA and Adjusted EBITDA as measures to assess the relative level of our indebtedness and our compliance with certain debt covenants which are based on these measures. Additionally, we utilize these measures to assess our operating and financial performance. We believe that these measures enhance a user’s understanding of normal operating income excluding certain charges, depreciation and amortization.

Neither EBITDA or Adjusted EBITDA are measures of financial performance computed in accordance with Generally Accepted Accounting Principles (“GAAP”) and should not be considered in isolation nor as a substitute for operating income, net income, cash flows from operations, or other statement of operations or cash flow data prepared in conformity with GAAP, or as a measure of profitability or liquidity. In addition, the calculation of EBITDA and Adjusted EBITDA is susceptible to varying interpretations and calculations, and the amounts presented may not be comparable to similarly titled measures of other companies. EBITDA and Adjusted EBITDA may not be indicative of historical operating results, and we do not intend these measures to be predictive of future results of operations.

		For the Three Months Ended September 30,									For the Nine Months Ended September 30,
		2020					2019				2020					2019
Net income - as reported (GAAP)		$	6,815				$	5,691			$	22,121				$	8,775
Adjustments to calculate EBITDA:
Depreciation and amortization		8,803					9,373				26,513					26,906
Interest expense, net		8,013					8,954				24,918					25,973
Non-service defined benefit plan expense		158					173				474					519
(Benefit) provision for income taxes		(1,911		)			2,585				(4,750		)			3,260
Adjustments - net income to EBITDA		15,063					21,085				47,155					56,658
EBITDA (Non-GAAP)		21,878					26,776				69,276					65,433
Further adjustments to calculate Adjusted EBITDA:
Third-party professional fees		—					2,136				1,639					5,530
Equity-based compensation (a)		2,602					3,374				15,087					10,089
Acquisition-related expenses		33					350				405					848
Hanger supply chain implementation costs		376					—				806					—
Severance expenses		3,015					—				3,015					(11		)
Proceeds from grants under the CARES Act		(43		)			—				(20,576		)			—
Further adjustments - EBITDA to Adjusted EBITDA		5,983					5,860				376					16,456
Adjusted EBITDA (Non-GAAP)		$	27,861				$	32,636			$	69,652				$	81,889

(a) Equity- based compensation expense includes an incremental charge in the second quarter of 2020 under ASC 718, Stock Compensation of approximately $5.9 million related to the modification of certain equity awards granted in 2017.

Table 7 Hanger, Inc. Segment Reconciliation of Income From Operations to EBITDA and Adjusted EBITDA (Unaudited - in thousands)

EBITDA is defined as operating income before depreciation and amortization. Adjusted EBITDA is defined as operating income before certain charges, third-party professional fees in excess of normal amounts incurred in connection with our financial statement remediation, expenses associated with equity-based compensation, severance expenses, certain expenses incurred in connection with our acquisitions, proceeds received from grants under the CARES Act and certain other charges.

We use EBITDA and Adjusted EBITDA as measures to assess the relative level of our indebtedness and our compliance with certain debt covenants which are based on these measures. Additionally, we utilize these measures to assess our operating and financial performance. We believe that these measures enhance a user’s understanding of normal operating income excluding certain charges, depreciation and amortization.

Neither EBITDA or Adjusted EBITDA are measures of financial performance computed in accordance with Generally Accepted Accounting Principles (“GAAP”) and should not be considered in isolation nor as a substitute for operating income, net income, cash flows from operations, or other statement of operations or cash flow data prepared in conformity with GAAP, or as a measure of profitability or liquidity. In addition, the calculation of EBITDA and Adjusted EBITDA is susceptible to varying interpretations and calculations, and the amounts presented may not be comparable to similarly titled measures of other companies. EBITDA and Adjusted EBITDA may not be indicative of historical operating results, and we do not intend these measures to be predictive of future results of operations.

		For the Three Months Ended September 30,										For the Nine Months Ended September 30,
		2020					2019					2020					2019
Patient Care
Income from operations - as reported (GAAP)		$	32,238				$	36,130				$	102,394				$	93,661
Depreciation & amortization		4,786					4,943					14,089					13,997
EBITDA (Non-GAAP)		37,024					41,073					116,483					107,658
Further adjustments to calculate Adjusted EBITDA:
Equity-based compensation		925					1,087					3,181					3,282
Hanger supply chain implementation costs		263					—					600					—
Severance expenses		1,040					—					1,040					(11		)
Proceeds from grants under the CARES Act		(43		)			—					(20,576		)			—
Further adjustments - EBITDA to Adjusted EBITDA		2,185					1,087					(15,755		)			3,271
Adjusted EBITDA (Non-GAAP)		39,209					42,160					100,728					110,929
Products & Services
Income from operations - as reported (GAAP)		5,121					5,111					12,959					14,133
Depreciation & amortization		2,633					2,723					7,883					7,862
EBITDA (Non-GAAP)		7,754					7,834					20,842					21,995
Further adjustments to calculate Adjusted EBITDA:
Equity-based compensation		244					236					690					726
Hanger supply chain implementation costs		113					—					206					—
Severance expenses		46					—					46					—
Further adjustments - EBITDA to Adjusted EBITDA		403					236					942					726
Adjusted EBITDA (Non-GAAP)		8,157					8,070					21,784					22,721
Corporate & Other
Loss from operations - as reported (GAAP)		(24,284		)			(23,838		)			(72,590		)			(69,267		)
Depreciation & amortization		1,384					1,707					4,541					5,047
EBITDA (Non-GAAP)		(22,900		)			(22,131		)			(68,049		)			(64,220		)
Further adjustments to calculate Adjusted EBITDA:
Third-party professional fees		—					2,136					1,639					5,530
Equity-based compensation (a)		1,433					2,051					11,216					6,081
Acquisition related expenses		33					350					405					848
Severance expenses		1,929					—					1,929					—
Further adjustments - EBITDA to Adjusted EBITDA		3,395					4,537					15,189					12,459
Adjusted EBITDA (Non-GAAP)		(19,505		)			(17,594		)			(52,860		)			(51,761		)
Total Adjusted EBITDA (Non-GAAP)		$	27,861				$	32,636				$	69,652				$	81,889

(a) Equity- based compensation expense includes an incremental charge in the second quarter of 2020 under ASC 718, Stock Compensation of approximately $5.9 million related to the modification of certain equity awards granted in 2017.

Table 8 Hanger, Inc. Indebtedness (Unaudited - in thousands)
		As of September 30,					As of December 31,
		2020					2019
Debt:
Term Loan B		$	492,375				$	496,163
Revolving credit facility		—					—
Seller notes		29,208					9,005
Deferred payment obligation		4,000					—
Finance lease liabilities and other		3,606					2,033
Total debt before unamortized discount and debt issuance costs		529,189					507,201
Unamortized discount and debt issuance costs, net		(7,798		)			(8,328		)
Total debt		$	521,391				$	498,873
Current portion of long-term debt:
Term Loan B		$	5,050				$	5,050
Seller notes		21,893					3,175
Finance lease liabilities and other		848					527
Total current portion of long-term debt		27,791					8,752
Long-term debt		$	493,600				$	490,121
Net indebtedness:
Total debt before unamortized discount and debt issuance costs		$	529,189				$	507,201
Cash and cash equivalents		(147,510		)			(74,419		)
Net indebtedness		$	381,679				$	432,782

Table 9 Hanger, Inc. Key Operating Metrics
		As of and For the Three Months Ended September 30,				For the Nine Months Ended September 30,
		2020		2019		2020		2019
Same clinic revenue:
(Decline) growth rate on net revenue		(10.3)%		3.7%		(10.7)%		1.8%
(Decline) growth rate day adjusted (a)		(10.3)%		2.1%		(11.2)%		1.8%
Clinical locations:
Patient care clinics		704		695
Satellite clinics		110		106
Total clinical locations		814		801

(a) Same Clinic Revenue per Day - Same Clinic Revenue per Day normalizes revenue for the number of days a clinic was open in each comparable period. These measures are both non-GAAP and unaudited.